188 related articles for article (PubMed ID: 20131992)
1. Optimal management of uterine leiomyosarcoma.
O'Cearbhaill R; Hensley ML
Expert Rev Anticancer Ther; 2010 Feb; 10(2):153-69. PubMed ID: 20131992
[TBL] [Abstract][Full Text] [Related]
2. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital.
Dinh TA; Oliva EA; Fuller AF; Lee H; Goodman A
Gynecol Oncol; 2004 Feb; 92(2):648-52. PubMed ID: 14766261
[TBL] [Abstract][Full Text] [Related]
3. Patterns of failure following surgical resection for malignant pleural mesothelioma.
Jänne PA; Baldini EH
Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
[TBL] [Abstract][Full Text] [Related]
4. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).
Reed NS; Mangioni C; Malmström H; Scarfone G; Poveda A; Pecorelli S; Tateo S; Franchi M; Jobsen JJ; Coens C; Teodorovic I; Vergote I; Vermorken JB;
Eur J Cancer; 2008 Apr; 44(6):808-18. PubMed ID: 18378136
[TBL] [Abstract][Full Text] [Related]
5. Role of chemotherapy and biomolecular therapy in the treatment of uterine sarcomas.
Hensley ML
Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):773-82. PubMed ID: 21752717
[TBL] [Abstract][Full Text] [Related]
6. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma.
Giuntoli RL; Garrett-Mayer E; Bristow RE; Gostout BS
Gynecol Oncol; 2007 Jul; 106(1):82-8. PubMed ID: 17434579
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma.
Wu TI; Chang TC; Hsueh S; Hsu KH; Chou HH; Huang HJ; Lai CH
Gynecol Oncol; 2006 Jan; 100(1):166-72. PubMed ID: 16182349
[TBL] [Abstract][Full Text] [Related]
8. Analysis of treatment failures in patients with early-stage uterine leiomyosarcoma.
Gadducci A; Fabrini MG; Bonuccelli A; Moda S; Fanucchi A; Laddaga M; Facchini V
Anticancer Res; 1995; 15(2):485-8. PubMed ID: 7763027
[TBL] [Abstract][Full Text] [Related]
9. [Metastatic lung tumor from uterine leiomyosarcoma].
Nishida T; Shoji S; Itoh T; Minami H; Akizuki K; Ozuno I; Kageyama H; Ozaki I; Yamamoto K; Yamamoto A; Nishiyama N
Kyobu Geka; 2006 Dec; 59(13):1191-6. PubMed ID: 17163213
[TBL] [Abstract][Full Text] [Related]
10. Effect of adjuvant therapy on the risk of recurrence in early-stage leiomyosarcoma: A meta-analysis.
Chae SH; Shim SH; Chang M; Choi AY; Kang GG; Lee SJ; Kim SN
Gynecol Oncol; 2019 Sep; 154(3):638-650. PubMed ID: 31307664
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant and neoadjuvant therapy for gastric cancer.
Kelsen DP
Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
Kushner DM; Webster KD; Belinson JL; Rybicki LA; Kennedy AW; Markman M
Gynecol Oncol; 2000 Aug; 78(2):221-7. PubMed ID: 10926807
[TBL] [Abstract][Full Text] [Related]
13. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
Anticancer Res; 2003; 23(1B):729-32. PubMed ID: 12680175
[TBL] [Abstract][Full Text] [Related]
14. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
[TBL] [Abstract][Full Text] [Related]
15. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
16. Treatment of uterine leiomyosarcoma.
Berchuck A; Rubin SC; Hoskins WJ; Saigo PE; Pierce VK; Lewis JL
Obstet Gynecol; 1988 Jun; 71(6 Pt 1):845-50. PubMed ID: 2453004
[TBL] [Abstract][Full Text] [Related]
17. Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?
Ricci S; Giuntoli RL; Eisenhauer E; Lopez MA; Krill L; Tanner EJ; Gehrig PA; Havrilesky LJ; Secord AA; Levinson K; Frasure H; Celano P; Fader AN
Gynecol Oncol; 2013 Dec; 131(3):629-33. PubMed ID: 24016408
[TBL] [Abstract][Full Text] [Related]
18. Options for Adjuvant Therapy for Uterine Leiomyosarcoma.
Friedman CF; Hensley ML
Curr Treat Options Oncol; 2018 Feb; 19(2):7. PubMed ID: 29417238
[TBL] [Abstract][Full Text] [Related]
19. Limitations of adjuvant radiotherapy for uterine sarcomas spread beyond the uterus.
Dusenbery KE; Potish RA; Judson P
Gynecol Oncol; 2004 Jul; 94(1):191-6. PubMed ID: 15262141
[TBL] [Abstract][Full Text] [Related]
20. Current trials and new aspects in soft tissue sarcoma of adults.
Issels RD; Schlemmer M
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S4-8. PubMed ID: 12042982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
